Epizyme (EPZM) Tops Q2 EPS by 10c

Epizyme (NASDAQ: EPZM) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• SAP Q1 results fall short of Wall Street estimates as transformation kicks off
• Independent Bank Group (IBTX) Tops Q1 EPS by 4c
• Cadence Bancorporation (CADE) Tops Q1 EPS by 8c